Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Specialty pharmaceutical company Targeted Medical Pharma in Los Angeles, US, has reported preliminary data from an open-label pilot study of its amino acid-based oral formulation.
Subscribe to our email newsletter
The PERCURA, a medical food, is formulated to reduce symptoms of pain and numbness in patients with peripheral neuropathy related to diabetes.
The study, after the first 30 days of treatment, demonstrated that the medical food reduced symptoms of numbness in subjects related to peripheral neuropathy at an average of 57% and pain at 56%.
Targeted Medical Pharma CEO and chief scientific officer William Shell said in 30% of the 20 million people, diabetes is the cause leading to peripheral neuropathy.
"Our medical foods treat the nutritional deficiencies found in chronic disease such as diabetes by providing the necessary amino acids to improve clinical outcomes without the negative side effects usually associated with pharmaceutical drugs," Shell added.
The company said all subjects are expected to complete the 60-day study by the end of 2012.